AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02399566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib, Pemetrexed
Description: followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
Study NCT02399566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib, Pemetrexed
Description: followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
Study NCT01085487 — intervention group
Intervention type: DRUG
Intervention: Hormonal treatment
Description: Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
Study NCT00090051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Intravenous repeating dose
Study NCT00090051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Intravenous repeating dose
Study NCT00090051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Intravenous repeating dose
Study NCT00090051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Intravenous repeating dose
Study NCT00803374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study NCT00803374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study NCT00803374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study NCT00803374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study NCT00803374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AntiCD137
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
Study NCT00803374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
Study NCT02266914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography driver
Description: A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
Study NCT02688712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Small molecule inhibitor of transforming growth factor-beta signaling pathway
Study NCT02688712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Antimetabolite chemotherapy
Study NCT02688712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Antimetabolite chemotherapy
Study NCT02688712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor specific mesorectal excision
Description: Tumor specific mesorectal excision
Study NCT02219555 — intervention group
Intervention type: PROCEDURE
Intervention: Carpel Tunnel surgery
Description: Standard of care carpel tunnel surgery
Study NCT03696173 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT03954041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB093
Description: Administered as specified in the treatment arm.
Study NCT03954041 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study NCT00638807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule once daily with morning meal for 6 weeks
Study NCT00638807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo for 6 weeks
Study NCT02777736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: i.v. or intrathecal CNS prophylaxis
Study NCT02777736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: i.v. or intrathecal CNS prophylaxis
Study NCT01655264 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based self training exercises for weak upper extremity
Description: Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
Study NCT03054454 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Podiatry
Description: Podiatry treatments and care from the multidisciplinary team.
Study NCT01085487 — intervention group
Intervention type: DRUG
Intervention: Antifibrinolytic treatment
Description: Antifibrinolytic treatment (such as tranexamic acid)
Study NCT04006860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHC014748M Capsules
Description: SHC014748M Capsules: 200mg
Study NCT01525979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-related unilateral arm training
Description: The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.
Study NCT01525979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-related bilateral arm training
Description: This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.
Study NCT01525979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted bilateral arm training
Description: The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.
Study NCT01525979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted unilateral arm training
Description: The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
Study NCT03829969 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy
Study NCT03829969 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Toripalimab
Description: TORIPALIMAB INJECTION(JS001 ) combine with chemotherapy or placebo combine with chemotherapy
Study NCT04688021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 4 mg/m2/day administered IV day -10 through -9.
Study NCT04688021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 3.2 mg/kg/day administered IV day -8 through -6.
Study NCT01655264 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation exercises for weak upper extremity
Description: The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
Study NCT04688021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1.8 g/m2/day administered IV day -5 through -4.
Study NCT04688021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Me-CCNU
Description: 250mg/m2 once administered orally on day -3.
Study NCT04688021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Description: 1.5mg/kg/day administered IV day -5 through -2.
Study NCT04688021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8mg/kg administered IV on day -1.
Study NCT04688021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HSCT
Description: Day 0
Study NCT04688021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: 2.5 mg/kg/day administered intravenously from day -7, target: 200-300ng/mL. Usually tapered during the second month, and ended in complete withdrawal during the ninth month after transplantation.
Study NCT04688021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 500 mg/day administered intravenously from day -9, ended in complete withdrawal on day +100.
Study NCT04688021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: 15 mg/m2 administered intravenously on day +1, 10mg/m2 on day +3, +6, and +9.
Study NCT02147990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Description: Rociletinib will be administered to patients orally
Study NCT01391156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3%Minoxidil lotion
Description: 3% Minoxidil lotion apply two times a day
Study NCT01391156 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3% Minoxidil with 0.1% Finasteride lotion
Description: 3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
Study NCT03635177 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
Study NCT03635177 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Four weeks of daily ischemic conditioning and four weeks of sham ischemic conditioning in a cross over design
Study NCT01556243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study NCT01556243 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole breast irradiation
Study NCT02393664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol, bupivacaine
Description: Nonintubated technique for thoracoscopic surgery using propofol infusion, intercostal and vagal blocks with bupivacaine infiltrations.
Study NCT02393664 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane, rocuronium
Description: Conventional intubated general anesthesia for thoracoscopic surgery using sevoflurane and rocuronium, and tracheal intubation with a double-lumen tube or a endobronchial blocker.
Study NCT05750511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: molecular tissue analysis
Study NCT02685384 — intervention group
Intervention type: OTHER
Intervention: Medicaid Expansion
Description: There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
Study NCT00943293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
Study NCT00943293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 140 mg/m2 IV on day -2.
Study NCT00943293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath
Description: Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
Study NCT04549168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: Lemborexant 10 mg tablet.
Study NCT04549168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet matched to lemborexant 10 mg tablet.
Study NCT02530151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine with clonidine
Description: see arm description
Study NCT02530151 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: see arm description
Study NCT01571089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DBT-inspired anxiety treatment
Description: In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
Study NCT03895476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: palatal wound will be cover with collagen and sutures
Description: after harvesting the graft from the palate, a collagen sponge will be sutured to cover the harvested site
Study NCT03812289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03812289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03895476 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: palatal wound covered with platelet rich fibrin
Description: after harvesting the graft from the palate the platelet rich fibrin will be sutured to covered the harvested site
Study NCT03812289 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study NCT04274179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet
Description: Low carb (20g/day), high fat, moderate protein diet. Started as an outpatient in clinic.
Study NCT04274179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Absence epilepsy medications
Description: At neurologist's discretion. \*OF NOTE\< THIS ARM IS COMPLETED
Study NCT00676650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 37.5 mg/day, oral, administered on a continuous daily dosing regimen
Study NCT00676650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: 5 mg BID, oral
Study NCT02068885 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feeding study
Description: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
Study NCT02068885 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeding study
Description: Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
Study NCT02437851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery to remove anal or perianal cancer (SISCCA)
Study NCT03526445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (4 ng/kg/min)
Study NCT03526445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo
Study NCT01374490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crofelemer
Description: Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
Study NCT00865956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Management
Description: Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
Study NCT00865956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Nurse case manager assigned to participant
Study NCT01266577 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NSR MAGNETOM 7T
Description: The 7 Tesla scanner is a magnet system used to acquire magnetic resonance imaging and spectroscopy
Study NCT01266577 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1Tx x 32Rx Head Coil
Description: Used to perform proton imaging and spectroscopy in the human heads.
Study NCT00756639 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation (PCI)
Description: Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
Study NCT02825316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Description: Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
Study NCT02825316 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low residue diet
Description: Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
Study NCT00569660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75 mg/m\^2 subcutaneous daily for 7 days (every 4 week cycle)
Study NCT02132650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACC training
Description: Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
Study NCT02132650 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SS training
Description: Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
Study NCT00604916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standardized oral care protocol - electronic toothbrush
Description: a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
Study NCT00604916 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mimic protocol
Description: a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
Study NCT03506841 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cerebrolysin
Description: Cerebrolysin injections of 0.1 mL/kg body weight for 3 months (total of twelve injections).
Study NCT00881231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)
Study NCT00881231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)
Study NCT03845491 — intervention group
Intervention type: DEVICE
Intervention: Mechanical Thrombectomy
Description: Treatment of LVO with mechanical thrombectomy
Study NCT03943134 — intervention group
Intervention type: OTHER
Intervention: Minimally Processed Human Umbilical Cord Membrane
Description: Implantation of minimally processed human umbilical cord membrane at the time of surgery
Study NCT03943134 — intervention group
Intervention type: OTHER
Intervention: Standard Surgical Procedures
Description: Standard surgical intervention for at least one targeted acute upper extremity trauma
Study NCT03281096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine hydrochloride
Description: patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
Study NCT03281096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: pill manufactured to mmic Berberine hydrochloride 100mg tablet
Study NCT04742608 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tissue samples
Study NCT04742608 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical charts are reviewed
Study NCT02912767 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.